An exploratory analysis from the IMpower010 trial adds support to the use of post-chemotherapy adjuvant immunotherapy for selected early stage non-small-cell lung cancer

Data from SECOMBIT provide useful insights to the optimal sequence of immune checkpoint inhibitor therapy and targeted treatment combinations for patients with BRAF-mutated, advanced melanoma 

Results from the ATALANTE-1 and MRTX-500 trials show efficacy improvements with immunotherapy in patients post-immune checkpoint inhibitor failure

Adding an immune checkpoint inhibitor to cetuximab plus radiotherapy does not improve outcomes versus standard of care in locally advanced squamous cell carcinoma of the head and neck

Phase III data highlight the consistent benefit of anti-PD-1 therapy for oesophageal and gastric cancer patients, with greatest benefit in high PD-L1-expressing tumours

Trials provide insights into perioperative and adjuvant chemotherapy for resectable pancreatic cancer

Positive in vitro and in vivo antitumour effects in breast and lung cancer models and in mismatch repair-driven cancer models

Significant, but clinically modest, prolongation of radiographic progression-free survival and event-free survival was achieved with darolutamide in the SAKK 08/16 study

Two phase I trials in patients with advanced EGFR-mutated NSCLC demonstrate promising potential of targeted therapy with amivantamab plus lazertinib